EastWest Announces Change of Directors

VANCOUVER, BC / ACCESSWIRE / December 11, 2018 / EastWestBioscience (formerly HarbourStar Capital Inc.) (the "Company" or"EastWest") (TSXV: EAST) announces that Mr. Mohammad Fazil has resigned as a director effectiveas of December 4, 2018, the Company wishes to thank Mr. Fazil for his years ofservice to Harbour Star Capital Inc. and assistance following completion of the qualifying transaction, asset out in the press release issued by the Company on July 23, 2018.

The Board of Directors of EastWest is now comprised of Rodney Gelineau,Scott Reeves, Douglas Horne and Nathan Lidder.

AboutEastWest BioScience Group

EastWest Bioscience is a seed-to-saleorganization that offers world class manufacturing and premium hemp-basedconsumer goods. Since it was founded in 2016, EastWest continues to grow as ahigh-quality producer, manufacturer and distributor of multiple lines ofpremium hemp products. EastWest is strategically positioned in mainstreamconsumer markets with wholistic natural products and has developed distributionchannels into mainstream stores and markets in Canada. The Company has a HealthCanada licensed, GMP (Good Manufacturing Practices) certified manufacturingfacility and produces premium brands offering natural products for a preventivecare lifestyle. EastWest consumer product lines are divided into four distinctbrands: 1) Natural Advancement – natural biopharmaceutical health supplements;2) Earth's Menu – all-natural hemp superfoods; 3) Natural Pet Science – petfood and pet supplements; and 4) Chanvre Hemp – all-natural health and beautyproducts. The organization will continue to focus on ongoing development ofinnovative, hemp-based consumer products through advanced science with clean,natural ingredients to complement its current product offerings.

ON BEHALF OFTHE BOARD OF DIRECTORS
EASTWESTBIOSCIENCE GROUP

"RodneyGelineau"
Co-Founder, Chief Executive Officer, Presidentand Director

For further information, please visitwww.eastwestbioscience.com or contact EastWest Bioscience Investor Relations at1-647-394-7383 or email us at [email protected].

Reader Advisory

This news release may contain statements which constitute "forward-lookinginformation", including statements regarding the plans, intentions, beliefs andcurrent expectations of the Company, its directors, or its officers withrespect to the future business activities of the Company. The words "may","would", "could", "will", "intend", "plan", "anticipate", "believe","estimate", "expect" and similar expressions, as they relate to the Company, orits management, are intended to identify such forward-looking statements.Investors are cautioned that any such forward-looking statements are notguarantees of future business activities and involve risks and uncertainties,and that the Company's future business activities may differ materially fromthose in the forward-looking statements as a result of various factors, including, but not limited to, fluctuationsin market prices, successes of the operations of the Company, continuedavailability of capital and financing and general economic, market or businessconditions. There can be no assurances that such information will proveaccurate and, therefore, readers are advised to rely on their own evaluation ofsuch uncertainties. The Company does not assume any obligation to update anyforward-looking information except as required under the applicable securitieslaws.

Neither TSXVenture Exchange nor its Regulation Services Provider (as that term is definedin policies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

SOURCE: EastWest Bioscience Inc.